{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:45:49Z","timestamp":1770338749584,"version":"3.49.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic> (<jats:italic toggle=\"yes\">H pylori)<\/jats:italic> infection can cause chronic gastritis, peptic ulcer, and even gastric cancer, so effective eradication is critical.<\/jats:p>\n            <jats:p>This study compared the efficacy and safety of bismuth quadruple regimens including either tetracycline or furazolidone for initial eradication.<\/jats:p>\n            <jats:p>Patients newly diagnosed with <jats:italic toggle=\"yes\">H pylori<\/jats:italic> infection from January 2020 to January 2021 were randomly assigned to receive either the tetracycline-containing regimen (n\u200a=\u200a116) or furazolidone-containing regimen (n\u200a=\u200a168). Both regimens included 1 proton pump inhibitor (rabeprazole 20\u200amg, or esomeprazole 20\u200amg, or eprazole 5\u200amg), colloidal pectin bismuth 300\u200amg, and amoxicillin 1000\u200amg in addition to tetracycline 1.0\u200ag or furazolidone 0.1\u200ag. All drugs were administered twice daily for 12 consecutive days. The <jats:sup>14<\/jats:sup>C urea breath test was used for diagnosis, and re-test negativity at one-month follow-up was considered successful eradication. Adverse events were recorded during follow-up by telephone interview.<\/jats:p>\n            <jats:p>In total, 109 patients in the tetracycline group and 157 in the furazolidone group were re-examined at 1\u200amonth. In the tetracycline group, 101 patients tested negative at follow-up, yielding an eradication rate of 92.7% according to per-protocol analysis and 87.1% by intention-to-treat analysis. In the furazolidone group, 141 patients tested negative, yielding eradication rates of 89.8% by PP and 83.9% by ITT. Eradication rates did not differ significantly between regimens (per-protocol: <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a0.637, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.517; intention-to-treat: <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a0.537, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.501). However, total adverse events incidence was significantly lower in the tetracycline group (20.2% vs 37.6%; <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a9.193, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.003).<\/jats:p>\n            <jats:p>Both bismuth quadruple regimens produce high initial eradication, but the tetracycline regimen appears safer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028323","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T19:19:37Z","timestamp":1640287177000},"page":"e28323","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-2285","authenticated-orcid":false,"given":"Junxian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1055-9965.EPI-17-1084","article-title":"Helicobacter pylori Blood biomarkers and gastric cancer survival in China","volume":"27","author":"Varga","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.beha.2017.01.002","article-title":"Clinical aspects and therapy of gastrointestinal MALT lymphoma","volume":"30","author":"Thieblemont","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-5378.2002.00097.x","article-title":"Relationship between gastric ulcer and Helicobacter pylori VacA detected in gastric juice using bead-ELISA method","volume":"7","author":"Shirasaka","year":"2002","journal-title":"Helicobacter"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.gastro.2015.09.004","article-title":"Pathobiology of Helicobacter pylori-induced gastric cancer","volume":"150","author":"Amieva","year":"2016","journal-title":"Gastroenterology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s10620-017-4536-8","article-title":"Primary antibiotic resistance of Helicobacter pylori in China","volume":"62","author":"Hu","year":"2017","journal-title":"Dig Dis Sci"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e12591","DOI":"10.1111\/hel.12591","article-title":"Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice","volume":"24","author":"Song","year":"2019","journal-title":"Helicobacter"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s10620-019-05694-4","article-title":"Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA","volume":"64","author":"Alsamman","year":"2019","journal-title":"Dig Dis Sci"},{"key":"R9-20250504","first-page":"01","article-title":"Cost-effectiveness of the carbon-13 urea breath test for the detection of Helicobacter pylori: an economic analysis","volume":"13","author":"Masucci","year":"2013","journal-title":"Ont Health Technol Assess Ser"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3748\/wjg.v13.i6.925","article-title":"Validity and cost comparison of 14carbon urea breath test for diagnosis of H Pylori in dyspeptic patients","volume":"13","author":"Rasool","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/gut.2003.022111","article-title":"H. pylori antibiotic resistance: prevalence, importance, and advances in testing","volume":"53","author":"Megraud","year":"2004","journal-title":"Gut"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.3748\/wjg.v13.i22.3147","article-title":"Treatment of duodenal ulceration with Furazolidone in China preceded the discovery of its association with H pylori","volume":"13","author":"Tovey","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e12468","DOI":"10.1111\/hel.12468","article-title":"Furazolidone treatment for Helicobacter Pylori infection: a systematic review and meta-analysis","volume":"23","author":"Zhuge","year":"2018","journal-title":"Helicobacter"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2036.2003.01822.x","article-title":"Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication","volume":"19","author":"Fakheri","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.3748\/wjg.v21.i8.2522","article-title":"Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection?","volume":"21","author":"Lv","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1440-1746.2006.04291.x","article-title":"Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility","volume":"21","author":"Cheon","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2710.2007.00853.x","article-title":"Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study","volume":"32","author":"Heaton","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/hel.12085","article-title":"Ten day quadruple therapy comprising proton pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy","volume":"19","author":"Hsu","year":"2014","journal-title":"Helicobacter"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"Graham","year":"2010","journal-title":"Gut"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"11415","DOI":"10.3748\/wjg.v20.i32.11415","article-title":"Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection","volume":"20","author":"Xie","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2217\/14622416.8.9.1199","article-title":"CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor","volume":"8","author":"Furuta","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"e12596","DOI":"10.1111\/hel.12596","article-title":"High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial","volume":"24","author":"Yu","year":"2019","journal-title":"Helicobacter"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1093\/jac\/dkw118","article-title":"Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial","volume":"71","author":"Hong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.31557\/APJCP.2019.20.4.1243","article-title":"CYP2C19 genotype, CagA genotype and antibiotic resistant strain of Helicobacter pylori infection","volume":"20","author":"Auttajaroon","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1159\/000502287","article-title":"Dual therapy with Vonoprazan and Amoxicillin is as effective as triple therapy with Vonoprazan, Amoxicillin and Clarithromycin for eradication of Helicobacter pylori","volume":"101","author":"Furuta","year":"2020","journal-title":"Digestion"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/hel.12221","article-title":"Is there any difference in the eradication rate of helicobacter pylori infection according to the endoscopic stage of peptic ulcer disease?","volume":"20","author":"Seo","year":"2015","journal-title":"Helicobacter"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"06","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"03","DOI":"10.5152\/tjg.2016.0278","article-title":"Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance","volume":"28","author":"\u00c7ekin","year":"2017","journal-title":"Turk J Gastroenterol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/pathogens9030184","article-title":"Transformation of Helicobacter pylori into coccoi forms as a challenge for research determining activity of antimicrobial substances","volume":"9","author":"Krzy\u017cek","year":"2020","journal-title":"Pathogens"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:07:07Z","timestamp":1746338827000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":30,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028323","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"assertion":[{"value":"2021-06-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}